

Tau as the Converging Protein between Chronic Stress and Alzheimer's Disease Synaptic Pathology

Ioannis Sotiropoulos Nuno Sousa

Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, and ICVS/3B's – PT Government Associate Laboratory, Braga, Portugal

Key Words

Alzheimer's disease · Environment · Tau · Stress · Glucocorticoids · Synapse · Missorting

Abstract

Background: Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with a complex physiopathology and still undefined initiators. Several risk factors have been suggested for AD with recent evidence supporting an etiopathogenic role of chronic environmental stress and glucocorticoids (GCs, stress hormones) in the development of the disease. Indeed, both AD and chronic stress are associated with neuronal atrophy, synaptic loss and cognitive impairment. Our previous studies have demonstrated the aggravating role of stress and GCs on AD pathology, including Tau hyperphosphorylation and aggregation and cognitive deficits in various AD models. In light of the suggested involvement of Tau missorting in AD synaptotoxicity and the dual cytoplasmic and synaptic role of Tau, our recent studies focused on the possible role of Tau in the underlying cascades of stress/GC neuronal malfunction/atrophy in wild-type animals by monitoring the intracellular localization of Tau and its phosphorylation status in different cellular compartments. **Summary:** Biochemical, ultrastructural, behavioral and neurostructural analysis have helped demonstrate that prolonged GC administration leads to dendritic remod-


eling and spine atrophy and loss in the rat hippocampus triggering Tau missorting at hippocampal synapses with the participation of specific phosphorylated Tau isoforms in this synaptic accumulation. **Key Messages:** The above findings suggest that Tau plays an essential role in mediating the neurodegenerative effects of stress and GCs towards the development of AD pathology. In addition, they highlight the involvement of Tau missorting in mechanism(s) of synaptic atrophy, beyond AD adding to our limited knowledge of the mechanisms through which stress causes brain pathology.

© 2015 S. Karger AG, Basel

Tau Protein in and beyond Alzheimer's Disease

Improvements in life span over the last decades have, unfortunately, not been matched by improvements in the mental health span. The World Health Organization estimates that a leading cause of mental disability in the coming years will be Alzheimer's disease (AD), a disease that already affects more than 35 million people worldwide. To combat this brain disorder, clinical and basic research continues to strive to improve the mechanistic understanding of AD pathology which is characterized by: (i) the overproduction of amyloid- β (A β), a neurotoxic peptide which fibrillates and accumulates as senile plaques in the brain, and (ii) hyperphosphorylation of the cytoskel-

Fig. 1. The neurodegenerative potential of chronic stress and GCs may be mediated through Tau protein. Prolonged exposure to GCs and/or stress triggers the aberrant hyperphosphorylation of the cytoskeletal protein Tau (p-Tau; mainly localized in axons; red in the healthy neuron), through the activation of different kinases (e.g. GSK3- β and cdk5). This leads to the somatodendritic accumulation as well as synaptic misrouting of Tau (red in diseased neuron), leading to neuronal malfunction and synaptic loss as well as cognitive impairment.



etal protein Tau which accumulates in neuronal soma as insoluble aggregates and neurofibrillary tangles [1, 2]. Sequential cleavage of the transmembrane protein amyloid precursor protein by β - and γ -secretases yields A β ; this cellular pathway is called amyloid precursor protein (APP) misprocessing. Numerous studies have causally linked A β to synaptic malfunction, neuronal atrophy and synaptic loss. In addition, it has been suggested that A β also triggers the other neurodegenerative mechanism of AD, the abnormal Tau hyperphosphorylation, leading to the formation of Tau aggregates and neuronal atrophy and loss.

The potential key role played of Tau in AD gained recognition relatively recently, and the protein is now a target in several drug discovery programs aimed at AD [3]. There is now strong evidence that Tau mediates at least some of the neuro- and synaptotoxic effects of A β [4–7]. Accordingly, our own and other work has demonstrated that synaptic dysfunction and atrophy as well as memory impairments are accompanied by the accumulation of hyperphosphorylated Tau in synapses, implicating hyperphosphorylated tau in AD synaptic loss [8–10]. Interestingly, while it is generally known as an axonal protein with a role in microtubule stabilization and assembly, Tau was recently shown to be present at synapses where it acts as scaffold protein and interacts with various proteins/receptors that modulate synaptic signaling and plasticity [11, 12]; still, the exact role of Tau at synapses needs further investigation.

Increasingly, Tau is being recognized to play a key role in brain physiology and pathology that goes beyond AD. For example, Tau has been suggested to be an essential mediator of different neuropathological processes beyond AD, e.g. excitotoxicity and epileptogenesis; hereby, Tau depletion blocks the neuronal malfunction damage and behavioral deficits [13–15]. Further, our previous work indicated that Tau may lie at the core of chronic

stress-induced pathological aging of the brain [10, 16]. Those findings proposed that Tau hyperphosphorylation may be a critical mechanism through which chronic stress and glucocorticoids (GCs, stress hormones) initiate neuropathological events that precipitate AD pathology [17]. Together, the above findings highlight Tau as a potential key modulator of neuronal and synaptic function during healthy and pathological brain states.

Chronic Stress and GCs as Precipitators of AD Pathology

Several factors that place individuals at risk for developing AD have been identified. Clinical evidence supports an etiopathogenic role for chronic stress and elevated GC levels in the development of AD pathology (fig. 1). Human studies suggest that exposure to chronic stress advances the onset of familial AD [18, 19] while high levels of GCs have been reported in the blood plasma, saliva and cerebrospinal fluid of AD patients [20–24]; the increased GC levels commonly associate with memory deficits in these patients [25, 26]. Since chronic elevation of GC levels is known to impair memory and other cognitive functions, it appears likely that GCs contribute to the progressive cognitive decline observed in AD. The hippocampus is a principal target of GC actions, and hippocampal neurons express the highest levels of GC receptors in the brain. The hippocampus is early affected in AD, and its dysfunction results in impairments in declarative, spatial and contextual memory. These facts, together with the important part played by the hippocampus in restraining GC secretion and, thus, regulating physiological mechanisms of stress response, have made this brain region a focus of research fields of both stress and AD raising the question of how high GC levels and chronic stress

impact the deterioration of hippocampal functions related to toxic A β and Tau hyperphosphorylation.

Previous studies from our own and other laboratories showed that exposure to chronic stress or prolonged treatment with the synthetic GC dexamethasone result in increased APP misprocessing and A β production in the hippocampus of AD animal models in parallel with memory deficits [27–29]. Further, we and others have shown that chronic stress and/or GC treatment trigger Tau hyperphosphorylation in neuronal somata in various animal models of AD; notably, these treatments hyperphosphorylated several Tau epitopes [10, 27] known to be associated with cytoskeletal pathology, synaptic loss and hippocampal atrophy as well as impairments of memory, speed of mental processing, and executive functions in AD patients (e.g. pSer262, pThr231) [30–35]. Our own work also demonstrated that GC treatment and chronic stress increased Tau accumulation by affecting turnover of the protein [10, 16], indicating that GCs may reduce Tau degradation through dysregulation of molecular chaperones responsible for tau proteostasis (e.g. heat-shock proteins Hsp90 and Hsp70) [36]. Interestingly, Hsp90 and Hsp70 serve to maintain GC receptors in a high-affinity state, thus suggesting a point at which GC/GC receptor signaling and Tau degradation machinery can intersect. The reduced Tau degradation could also facilitate the increased aggregation of Tau into insoluble forms triggered by stress in P301L-Tau Tg mice (mice expressing human tau carrying the most common Tau mutation P301L) [36]. In this last study, chronic stress was shown to promote C-terminal truncation of Tau by caspase-3 and abnormal conformation of Tau in the hippocampus of P301L-Tau Tg mice. Together with Tau hyperphosphorylation, both truncation and abnormal conformation of tau precede its aggregation and formation of neurofibrillary tangles [37–39], thus serving as early markers of disease.

Tau Accumulation: Linking Stress with Synaptic Pathology and AD?

Recent human and animal studies suggest that mislocated Tau, due to missorting in dendritic spines and synapses, underpins the synaptic pathology found in AD [8, 40–42]. This could possibly explain the known correlation between Tau hyperphosphorylation and synaptic loss and memory impairment in experimental animals [9, 40], and such a mechanism could also possibly explain how stress results in synapse and memory loss. These hy-

potheses are indeed supported by very new studies in our laboratory that implicate Tau missorting in GC-triggered hippocampal pathology in wild-type animals [43]. We demonstrated, both by biochemical (subcellular fractionation) and ultrastructural (electron microscope) analysis, that prolonged GC administration in wild-type animals led to cytosolic and dendritic Tau accumulation in the rat hippocampus and triggered Tau hyperphosphorylation in epitopes related to its malfunction (Ser396/404) and cytoskeletal pathology (e.g. Thr231 and Ser262). In addition, we show that chronic GC administration also increased Tau levels in the synaptic compartment related to dendritic remodeling and synaptic loss exhibiting a preferential subcellular accumulation of different Tau isoforms in different intracellular compartments [43]. Overall, these recent findings from our laboratory support a role for Tau and its missorting in GC-induced dendritic remodeling and synaptic loss.

This brief review highlights the essential role of Tau protein in the neurodegenerative potential of chronic stress and GC towards the development of AD. It also summarizes the emerging evidence that Tau missorting may be a common mechanism in both AD and stress-related disorders of the brain adding to our knowledge about the poorly understood cellular cascades of stress-related brain pathology.

Disclosure Statement

The authors have no conflicts of interest to declare.

References

- 1 Ittner LM, Gotz J: Amyloid- β and tau – a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci* 2011;12:65–72.
- 2 Spillantini MG, Goedert M: Tau pathology and neurodegeneration. *Lancet Neurol* 2013;12:609–622.
- 3 Yoshiyama Y, Lee VM, Trojanowski JQ: Therapeutic strategies for tau mediated neurodegeneration. *J Neurol Neurosurg Psychiatry* 2013;84:784–795.
- 4 Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A: Tau is essential to beta-amyloid-induced neurotoxicity. *Proc Natl Acad Sci USA* 2002;99:6364–6369.
- 5 Roberson ED, Scarce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L: Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science* 2007;316:750–754.
- 6 Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L: Tau reduction prevents Abeta-induced defects in axonal transport. *Science* 2010;330:198.

- 7 Vossel KA, Xu JC, Fomenko V, Miyamoto T, Suberbielle E, Knox JA, Ho K, Kim DH, Yu GQ, Mucke L: Tau reduction prevents Abeta-induced axonal transport deficits by blocking activation of GSK3beta. *J Cell Biol* 2015;209:419–433.
- 8 Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D: Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. *Neuron* 2010;68:1067–1081.
- 9 Kimura T, Fukuda T, Sahara N, Yamashita S, Murayama M, Miziroki T, Yoshike Y, Lee B, Sotiropoulos I, Maeda S, Takashima A: Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. *J Biol Chem* 2010;285:38692–38699.
- 10 Sotiropoulos I, Catania C, Pinto LG, Silva R, Pollerberg GE, Takashima A, Sousa N, Almeida OFX: Stress acts cumulatively to precipitate Alzheimer's disease-like TAU pathology and cognitive deficits. *J Neurosci* 2011;31:7840–7847.
- 11 Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfling H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. *Cell* 2010;142:387–397.
- 12 Kimura T, Whitcomb D, Jo J, Regan P, Piers T, Heo S, Brown C, Hashikawa T, Murayama M, Seok H, Sotiropoulos I, Kim E, Collingridge GL, Takashima A, Cho K: Microtubule associated protein tau (MAPT) is essential for long-term depression in the hippocampus. *Philos Trans R Soc Lond B Biol Sci* 2013;369:20130144.
- 13 Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devizé N, Yu GQ, Palop JJ, Noebels JL, Mucke L: Amyloid- β /Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. *J Neurosci* 2011;31:700–711.
- 14 Devos SL, Goncharoff DK, Chen G, Kebede CS, Yamada K, Stewart FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, Bennett CF, Cirrito JR, Holtzman DM, Miller TM: Antisense reduction of tau in adult mice protects against seizures. *J Neurosci* 2013;33:12887–12897.
- 15 Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin SG, Pautler RG, Botas J, Noebels JL: Tau loss attenuates neuronal network hyperexcitability in mouse and *Drosophila* genetic models of epilepsy. *J Neurosci* 2013;33:1651–1659.
- 16 Sotiropoulos I, Catania C, Reidman T, Fry J, Breen K, Michaelidis T, Almeida OFX: Glucocorticoids trigger Alzheimer disease-like pathobiochemistry in neuronal cells expressing human tau. *J Neurochem* 2008;107:385–397.
- 17 Sotiropoulos I, Cerqueira J, Catania C, Sousa N, Almeida OFX: Stress and glucocorticoid footprints in the brain – the path from depression to Alzheimer's disease. *Neurosci Biobehav Rev* 2008;32:1161–1173.
- 18 Simard M, Hudon C, van Reekum R: Psychological distress and risk for dementia. *Curr Psychiatry Rep* 2009;11:41–47.
- 19 Mejia S, Giraldo M, Pineda D, Ardila A, Lopera F: Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease. *Int Psychogeriatr* 2003;15:337–349.
- 20 Greenwald BS, Mathe AA, Mohs RC, Levy MI, Johns CA, Davis KL: Cortisol and Alzheimer's disease. II. Dexamethasone suppression, dementia severity, and affective symptoms. *Am J Psychiatry* 1986;143:442–446.
- 21 Hattinger M, Z'Brun A, Hemmeter U, Seifritz E, Baumann F, Holsboer-Trachsler E, Heuser JJ: Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. *Neurobiol Aging* 1995;16:205–209.
- 22 Rasmuson S, Andrew R, Nasman B, Seckl JR, Walker BR, Olsson T: Increased glucocorticoid production and altered cortisol metabolism in women with mild to moderate Alzheimer's disease. *Biol Psychiatry* 2001;49:547–552.
- 23 Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA: Increased CSF cortisol in AD is a function of APOE genotype. *Neurology* 2001;56:1094–1098.
- 24 Hoogendijk WJ, Meynen G, Endert E, Hofman MA, Swaab DF: Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression. *Neurobiol Aging* 2006;27:780.e1–e2.
- 25 Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris JC: Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. *Am J Psychiatry* 2006;163:2164–2169.
- 26 Elgh E, Lindqvist Astot A, Fagerlund M, Eriksson S, Olsson T, Nasman B: Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. *Biol Psychiatry* 2006;59:155–161.
- 27 Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM: Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. *J Neurosci* 2006;26:9047–9056.
- 28 Jeong YH, Park CH, Yoo J, Shin KY, Ahn SM, Kim HS, Lee SH, Emson PC, Suh YH: Chronic stress accelerates learning and memory impairments and increases amyloid deposition in AP-PV7171-CT100 transgenic mice, an Alzheimer's disease model. *FASEB J* 2006;20:729–731.
- 29 Catania C, Sotiropoulos I, Silva R, Onofri C, Breen KC, Sousa N, Almeida OFX: The amyloidogenic potential and behavioral correlates of stress. *Mol Psychiatry* 2009;14:95–105.
- 30 Callahan LM, Vauls WA, Coleman PD: Progressive reduction of synaptophysin message in single neurons in Alzheimer disease. *J Neuropathol Exp Neurol* 2002;61:384–395.
- 31 Lauckner J, Frey P, Geula C: Comparative distribution of tau phosphorylated at Ser262 in pre-tangles and tangles. *Neurobiol Aging* 2003;24:767–776.
- 32 Hampel H, Burger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, Leinsinger G, Evans AC, Davies P, Möller HJ, Teipel SJ: Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. *Arch Neurol* 2005;62:770–773.
- 33 Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. *Acta Neuropathol* 2002;103:26–35.
- 34 Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, Bouwman FH, Schönknecht P, Schoonenboom NS, Andreasen N, Wallin A, DeBernardis JF, Kerkman DJ, Heindl B, Blennow K, Hampel H: Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. *Neurology* 2007;69:2205–2212.
- 35 Van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM: CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. *Neurology* 2009;72:1056–1061.
- 36 Sotiropoulos I, Silva J, Kimura T, Rodrigues AJ, Costa P, Almeida OF, Sousa N, Takashima A: Female hippocampus vulnerability to environmental stress, a precipitating factor in tau aggregation pathology. *J Alzheimers Dis* 2015;43:763–774.
- 37 Weaver CL, Espinoza M, Kress Y, Davies P: Conformational change as one of the earliest alterations of tau in Alzheimer's disease. *Neurobiol Aging* 2000;21:719–727.
- 38 De Calignon A, Polydoro M, Suarez-Calvet M, Williams C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT: Propagation of tau pathology in a model of early Alzheimer's disease. *Neuron* 2012;73:685–697.
- 39 Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM: Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. *Proc Natl Acad Sci USA* 2007;104:10252–10257.
- 40 Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, Yoshiike Y, Sahara N, Takashima A: Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild-type human tau. *EMBO J* 2007;26:5143–5152.
- 41 Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT: The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. *Am J Pathol* 2012;181:1426–1435.
- 42 Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E, Mandelkow EM: Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TLL6 and spastin. *EMBO J* 2013;32:2920–2937.
- 43 Pinheiro S, Silva J, Mota C, Vaz-Silva J, Veloso A, Pinto V, Sousa N, Cerqueira JJ, Sotiropoulos I: Tau mislocation in glucocorticoid-triggered hippocampal pathology. *Mol Neurobiol* 2015, Epub ahead of print.